BeiGene's Brukinsa Crosses $2.5bn Annual Run-Rate As US Oncology-Market Share Continues To Expand

BeiGene's Brukinsa (zanubrutinib) franchise crossed the $2.5 billion annual run-rate threshold on the Q1 2026 commercial-revenue print disclosed Tuesday morning — confirming the molecule's positioning as the single-largest BTK-inhibitor product globally on contemporary prescription-volume measure and substantially strengthening the underlying BeiGene oncology-portfolio commercial-trajectory through the late-decade cycle.

The Q1 print, at approximately $675 million in disclosed Brukinsa revenue across the quarter, was approximately 39% ahead of the equivalent year-ago quarter and ahead of analyst consensus. The headline lift was driven by a combination of the substantial continued strong year-on-year volume-growth trajectory across the principal North American commercial market, the substantial international-market-expansion-rate across the principal European-and-Japanese commercial markets, and the meaningful pricing-and-mix uplift that has accompanied the progressively-broadening therapeutic-indication framework across the regulatory cycle.

The competitive-positioning dynamic continues to evolve. Brukinsa's commercial trajectory across the US chronic-lymphocytic-leukemia and broader-BTK-inhibitor-applicable-indication market has continued to substantially compound across the post-2023 commercial cycle, principally driven by the substantial head-to-head clinical-trial data the molecule has delivered against the principal competing first-generation BTK-inhibitor (AbbVie's Imbruvica) across the ALPINE and SEQUOIA Phase Three programmes. The US prescription-volume-market-share figure across the Q1 window, on company disclosure and IQVIA reference, reached approximately 41% of the addressable second-line-and-later CLL prescription-volume base — approximately 12 percentage points ahead of the equivalent year-ago measure and approximately 6 percentage points ahead of the parallel Imbruvica market-share figure.

The pipeline-development overlay continues to reinforce the underlying franchise picture. BeiGene's parallel BTK-degrader product candidate BGB-16673 — currently progressing through the late-stage Phase Two clinical programme — represents the principal medium-term successor candidate to the Brukinsa franchise and is on company guidance expected to deliver Phase Three commencement across the H2 2026 window. The wider BeiGene oncology pipeline includes approximately twelve additional Phase-Two-and-later programme candidates across the principal hematology, solid-tumour, and immunotherapy therapeutic categories.

For investors holding the wider BeiGene and broader oncology-pharmaceutical-sector complex, the Q1 Brukinsa print is the cleanest single confirmation that the franchise's commercial trajectory continues to compound through the post-original-launch cycle and that the underlying BeiGene strategic-positioning advantage across the global BTK-inhibitor market remains substantially intact. The principal forward variable through the rest of the year is the substantive progression of the broader Brukinsa-label-expansion programme — particularly the planned diffuse-large-B-cell-lymphoma combination data readouts and the parallel Waldenström-macroglobulinemia indication-broadening cycle that are expected to support the late-decade-revenue-trajectory framework.